Rapamycin (also known as sirolimus) is an immunosuppressant drug that is commonly used to prevent organ rejection after transplantation. It prevents activation of T cells and B cells by inhibiting their response to interleukin-2 (IL-2). Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates cell growth, motility, and survival in response to nutrient levels, as well as transcription and protein synthesis. Rapamycin inhibits mTOR activity by associating with the mTOR receptor, FKB12. mTOR functions as part of two complexes with distinct composition and cellular functions, known as mTORC1 and mTORC2. mTOR is also known as mechanistic target of rapamycin (serine/threonine kinase), FKBP-rapamycin associated protein (FRAP), FKBP12-rapamycin complex-associated protein 1 (FRAP1), FK506 binding protein 12-rapamycin associated protein 2 (FRAP2), rapamycin and FKBP12 target 1 (RAFT1), rapamycin target protein 1 (RAPT1), and FLJ44809.
This product is an affinity-purified IgG antibody that recognizes rat and human mTOR protein. The antibody was raised in mouse using recombinant rat mTOR protein, and can be used for Western blot (WB) detection or immunoprecipitation (IP) of rat and human mTOR protein.